Bjerre

About Steen Bjerre

This author has not yet filled in any details.
So far Steen Bjerre has created 152 blog entries.

Cinryze production has resumed

2017-10-27T23:11:50+00:00

Shire plc announces unaudited results for the three months ended September 30, 2017. Flemming Ornskov, M.D., M.P.H., Shire CEO, commented: “We delivered strong growth this quarter despite a Cinryze supply shortage. We experienced a product shortage of Cinryze during the quarter due to a manufacturing interruption at a third-party manufacturer. The issue has been addressed and production [...]

On the right track

2017-10-27T17:41:40+00:00

Pharming Group N.V. presents its (unaudited) financial report for the first nine months and the third quarter ended 30 September 2017. Operational highlights during the third quarter On September 11, following the conclusion of the End-of-Phase 2 interactions with the US Food and Drug Administration (FDA), Pharming announced that it will submit a supplemental Biologics [...]

European Approval for Label Extension of Firazyr

2017-10-26T23:38:12+00:00

The European Commission (EC) has approved a label extension granting a new indication for Firazyr (icatibant injection), broadening its use to adolescents and children aged 2 years and older, with HAE caused by C1-esterase-inhibitor (C1-INH) deficiency. Firazyr has been approved in the European Union (EU) since 2008 for symptomatic treatment of acute attacks of HAE in [...]

Positive data from paediatric clinical trial with Ruconest

2017-10-02T16:58:26+00:00

Pharming Group N.V. announces positive data from a clinical trial with the use of Ruconest [Recombinant Human C1 Esterase Inhibitor/ conestat alfa] for the treatment of HAE attacks in children. The open-label, single arm, Phase II clinical trial was designed in agreement with the European Medicines Agency (EMA) as part of a Paediatric Investigation Plan (PIP) [...]

Verseon developing oral treatment for HAE

2017-09-28T00:45:43+00:00

Verseon Corporation has announced the launch of a drug program developing oral treatments for HAE. In their interim report, the Company presents data from a well-established HAE disease model which demonstrate the efficacy of their plasma kallikrein inhibitors in reducing swelling. An oral therapeutic would be a life-changing development for HAE patients who currently rely on [...]

Pharming and HAEi partners with Inceptua for Global Access Program

2017-09-26T18:55:38+00:00

Pharming Group N.V in association with HAEi announce the appointment of Inceptua Medicines Access as their new distribution partner for the “HAEi Global Access Program” (HAEi GAP) enabling patients in all countries where Pharming’s product RUCONEST is not commercially available to gain access to the drug through an ethical and regulatory compliant mechanism.  It is [...]

Recommendations for Prophylaxis and Treatment of HAE Attacks

2017-09-18T03:48:07+00:00

The Food and Drug Administration (FDA) has recently received reports from patients, physicians, and specialty pharmacies that they have been unable to obtain C1-Esterase Inhibitor (Human) Cinryze. Healthcare providers and patients may wish to consider alternate treatment options, including: For Prophylaxis: Haegarda was recently licensed for prophylaxis of HAE attacks. Haegarda is administered subcutaneously, twice [...]

Diplomat acquires Focus Rx

2017-09-18T03:45:04+00:00

Diplomat Pharmacy, Inc. has completed its acquisition of Focus Rx Pharmacy Services Inc., a customer-focused healthcare partner that provides home infusion and specialty prescription management services. This acquisition bolsters Diplomat’s offering of extensive solutions to meet growing demand for infusion therapies. Diplomat’s specialty infusion services are built on the combined experience of experts in a [...]

Portfolio of Oral Plasma Kallikrein Inhibitors Continues to Advance

2017-09-16T03:09:52+00:00

  From the KalVista Pharmaceuticals, Inc. operational and financial results for the fiscal first quarter ended July 31, 2017: “We continue to make progress with our portfolio of oral plasma kallikrein inhibitors in pursuit of our goal of a best-in-class oral therapy for HAE,” said CEO Andrew Crockett. “We are completing the first-in-human trial of [...]

Significant reduction of attack rate

2017-09-16T03:04:21+00:00

Shire plc announces positive topline Phase 3 results for the Sahara study, a global, multi-center, randomized, double-blind, placebo-controlled, partial crossover trial that evaluated the efficacy and safety of subcutaneously administered C1 esterase inhibitor [human] Liquid for Injection, also referred to as SHP616 Liquid, versus placebo over two 14-week treatment periods in patients 12 years of [...]